GlassScriptPhysician profile
Serda C Hawthorne
NPI 1659507986
$4,996.66
in general payments reported to CMS, 2019-2025
32 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $177 · 2021: $478 · 2022: $545 · 2023: $1,101 · 2024: $1,127 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,251 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.00 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $539.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $434.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $407.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $367.37 | 2020-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.95 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $341.35 | 2021-2025 | |
| Pfizer INC. | $328.62 | 2019-2025 | |
| Astellas Pharma US INC | $321.16 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $288.36 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $207.27 | 2019-2025 | Trintellix |
| Amgen INC. | $206.17 | 2019-2025 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $159.19 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Edwards Lifesciences Corporation | $133.97 | 2024 | |
| Sumitomo Pharma America, INC. | $126.07 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.67 | 2019-2025 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $98.36 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $97.30 | 2019-2024 | Belsomra, Januvia, Steglatro |
| Phathom Pharmaceuticals, INC. | $65.31 | 2024-2025 | Voquezna |
| Harmony Biosciences LLC | $58.50 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $37.54 | 2019-2020 | |
| Axsome Therapeutics, INC. | $36.65 | 2025 | Auvelity |
| Amarin Pharma, INC. | $34.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.03 | 2024 | |
| Dexcom, INC. | $29.31 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $28.73 | 2019 | |
| Tonix Medicines, INC. | $26.06 | 2025 | Tonmya |
| Abbott Laboratories | $24.12 | 2023 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $22.34 | 2024 | Nexletol |
| Avanir Pharmaceuticals, INC. | $19.40 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.93 | 2023 | Gvoke Hypopen |
| Jazz Pharmaceuticals INC. | $16.24 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serda Hawthorne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.